Quantcast
Last updated on April 19, 2014 at 9:20 EDT

Latest Herceptin Stories

2013-10-14 08:25:25

Prime Therapeutics analysis finds nearly 76 percent of patients taking Herceptin were treated in early stage breast cancer - important for predicting breast cancer future costs ST. PAUL, Minn., Oct. 14, 2013 /PRNewswire/ -- Expanded use of the common breast cancer drug Herceptin® (trastuzumab) can be tracked using pharmacy and medical administrative claims data, according to a new analysis by pharmacy benefit manager Prime Therapeutics LLC (Prime). Prime will be presenting the study...

2013-09-26 16:27:00

SAN DIEGO, Sept. 26, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the commercial launch of Herceptin(®) SC in Europe has triggered a $10 million milestone payment to Halozyme under the License and Collaboration Agreement between Halozyme and Roche. This time-saving subcutaneous formulation of Herceptin (trastuzumab) using Halozyme's recombinant human hyaluronidase (rHuPH20) received marketing authorization from the European Commission on August...

2013-09-02 00:20:34

SAN DIEGO, Sept. 2, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that the European Commission has granted Roche European Union (EU) marketing authorization for the use of a time-saving subcutaneous (SC) formulation of Herceptin(®) (trastuzumab) for the treatment of HER2-positive breast cancer. This formulation utilizes Halozyme's recombinant human hyaluronidase (rHuPH20) and is administered in two to five minutes, rather than 30 to 90 minutes with...

2013-06-28 12:24:26

SAN DIEGO, June 28, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that Roche received a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for the subcutaneous formulation of Herceptin(®) (trastuzumab) using Halozyme's recombinant human hyaluronidase (rHuPH20) for the treatment of patients with HER2-positive breast cancer in Europe. (Logo;...

2013-06-02 08:20:17

-- A 22% reduction in the risk of disease progression was seen with the addition of everolimus, an mTOR inhibitor, to trastuzumab and vinorelbine in heavily pretreated patients(1) EAST HANOVER, N.J., June 2, 2013 /PRNewswire/ -- Novartis today presented results from a pivotal Phase III trial of a treatment regimen including Afinitor(®) (everolimus) tablets in women with human epidermal growth factor receptor-2 positive (HER2 positive) advanced breast cancer who received prior...

New Drug To Treat Breast Cancer Approved By US Regulatory Agency
2013-02-23 06:52:31

April Flowers for redOrbit.com - Your Universe Online The Food and Drug Administration (FDA) has approved a brand new type of breast cancer medication this week that targets tumor cells while sparing healthy surrounding tissues. In U.S. women, breast cancer is the second most deadly form of cancer and is expected to kill more than 39,000 Americans this year alone, the National Cancer Institute reports. Kadcyla, from Roche, is a combination of a powerful chemotherapy drug, the...

2012-12-10 08:25:23

MISSISSAUGA, ON, Dec. 10, 2012 /CNW/ - Roche today announced updated survival results from the Phase III CLEOPATRA study, which showed that the combination of Perjeta® (pertuzumab), Herceptin® (trastuzumab) and docetaxel chemotherapy significantly extended the lives (overall survival) of people with previously untreated HER2-positive metastatic breast cancer (mBC), compared to Herceptin, chemotherapy and placebo. Results showed that the risk of death was reduced by 34...

2012-09-05 21:19:07

A more-sensitive method to analyze protein interactions has uncovered a new way that cancer cells may use the cell-surface molecule HER3 to drive tumor progression following treatment with HER1 and HER2 inhibitors. The HER family of receptors has been linked to the development of a wide variety of human cancers. HER1 inhibitors such Iressa and HER2 inhibitors such as Herceptin are commonly used in the clinic for treatment of small cell lung carcinoma and breast cancer. A recent study...

2012-06-13 10:24:22

INCLINE VILLAGE, Nev., June 13, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced royalty revenue guidance for the second quarter ending June 30, 2012, of approximately $125 million, as compared with actual royalty revenue of $122 million for the second quarter of 2011, a two percent increase. (Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO) The forecasted growth in royalty revenues is driven by increased first quarter 2012 sales of...

New Cancer Drug Targets Tumor Cells, Reduces Side Effects
2012-06-04 02:57:24

A clinical trial of an experimental new breast cancer treatment found that it extended the life expectancy of patients without the symptoms of the disease worsening, various media outlets reported on Sunday. The drug, TDM-1, is manufactured by Roche, and according to Naomi Kresge and Robert Langreth of Bloomberg, it works by carrying chemotherapy directly into cancer cells while successfully avoiding healthy ones, resulting in fewer side effects than conventional treatments. According...